treatment-resistant depression
Supernus Pharmaceuticals’ Depression Drug SPN-820 Fails to Meet Primary Endpoint in Phase 2b Trial
Supernus Pharmaceuticals, SPN-820, treatment-resistant depression, Phase 2b trial, clinical study failure, MADRS score, placebo effect
Supernus Pharmaceuticals’ Stock Plummets as Phase 2b Depression Drug Trial Fails to Meet Primary Endpoint
Supernus Pharmaceuticals, SPN-820, treatment-resistant depression, clinical trial failure, stock decline, placebo effect
GH Research Reports Positive Phase 2b Results for Inhaled 5-MeO-DMT in Treatment-Resistant Depression
GH Research, 5-MeO-DMT, GH001, treatment-resistant depression, psychedelic therapy, clinical trial, Phase 2b